Cometa Therapeutics Inc.
Towson, MD
- UEI
- RNTBQE96PX23
- CAGE
- Not on record
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 22 W Pennsylvania Ave #411, Towson, MD 21204, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| ND enabling studies for CMT-101, a novel gene therapy for glycogen storage disease 1B - cornela therapeutics is a new… | National Institute of Diabetes and Digestive and Kidney Diseases | $1,444,679 |
Quick answers
What is Cometa Therapeutics Inc.'s UEI?
Cometa Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is RNTBQE96PX23.
Where is Cometa Therapeutics Inc. located?
Cometa Therapeutics Inc.'s physical address in SAM.gov is 22 W Pennsylvania Ave #411, Towson, MD 21204, USA.
Is Cometa Therapeutics Inc. registered in SAM.gov?
Yes. Cometa Therapeutics Inc.'s SAM.gov registration is active through July 6, 2027.
What is Cometa Therapeutics Inc.'s most recent federal award?
Cometa Therapeutics Inc.'s most recent federal grant award is ND enabling studies for CMT-101, a novel gene therapy for glycogen storage disease 1B - cornela therapeutics is a new… (R42DK141304), from National Institute of Diabetes and Digestive and Kidney Diseases, on June 1, 2025.
On GovTribe
See Cometa Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors